Relationship between lipoprotein B and the severity of coronary microvascular dysfunction.

IF 1.5 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Clinical and Experimental Hypertension Pub Date : 2025-12-01 Epub Date: 2025-03-18 DOI:10.1080/10641963.2025.2477651

Lili Yang, Jingjing Zhang, Jiangyan Han, Xiaojuan Jiang

{"title":"Relationship between lipoprotein B and the severity of coronary microvascular dysfunction.","authors":"Lili Yang, Jingjing Zhang, Jiangyan Han, Xiaojuan Jiang","doi":"10.1080/10641963.2025.2477651","DOIUrl":null,"url":null,"abstract":"Objective: Contributing factors for the development of heart failure (HF) involve both apolipoprotein B (ApoB) and coronary microvascular dysfunction (CMD). Although ApoB has been linked to diverse cardiovascular risks, its association with CMD remains unclear.Methods: A total of 145 patients undergoing cardiac single-photon emission computed tomography (SPECT) scan was enrolled into this retrospective study. Based on ApoB serum level, all subjects were classified into three groups (Group 1-3). Myocardial flow reserve (MFR) was calculated using myocardial blood flow (MBF) tested in different contexts.Results: ApoB serum level was positively correlated to rest MBF but inversely associated with stress MBF and MFR. Following adjustment for covariates, a significant relationship was observed between increased ApoB and decreased MFR. The predictive value of ApoB was test by Receiver Operating Characteristic Curve (ROC) analysis, showing an area under curve (AUC) of 0.87.Conclusion: The findings indicated that a higher level of ApoB correlated with the severity of CMD.","PeriodicalId":10333,"journal":{"name":"Clinical and Experimental Hypertension","volume":"47 1","pages":"2477651"},"PeriodicalIF":1.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2025.2477651","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Contributing factors for the development of heart failure (HF) involve both apolipoprotein B (ApoB) and coronary microvascular dysfunction (CMD). Although ApoB has been linked to diverse cardiovascular risks, its association with CMD remains unclear.

Methods: A total of 145 patients undergoing cardiac single-photon emission computed tomography (SPECT) scan was enrolled into this retrospective study. Based on ApoB serum level, all subjects were classified into three groups (Group 1-3). Myocardial flow reserve (MFR) was calculated using myocardial blood flow (MBF) tested in different contexts.

Results: ApoB serum level was positively correlated to rest MBF but inversely associated with stress MBF and MFR. Following adjustment for covariates, a significant relationship was observed between increased ApoB and decreased MFR. The predictive value of ApoB was test by Receiver Operating Characteristic Curve (ROC) analysis, showing an area under curve (AUC) of 0.87.

Conclusion: The findings indicated that a higher level of ApoB correlated with the severity of CMD.

查看原文本刊更多论文

脂蛋白B与冠状动脉微血管功能障碍程度的关系。

目的：载脂蛋白B （ApoB）和冠状动脉微血管功能障碍（CMD）共同影响心力衰竭（HF）的发生。尽管载脂蛋白ob与多种心血管风险有关，但其与CMD的关系尚不清楚。方法：对145例接受心脏单光子发射计算机断层扫描（SPECT）的患者进行回顾性研究。根据血清载脂蛋白b水平将所有受试者分为3组（1-3组）。心肌血流储备（MFR）是通过不同情况下心肌血流量（MBF）来计算的。结果：ApoB血清水平与休息MBF呈正相关，与应激MBF和MFR呈负相关。调整协变量后，观察到ApoB升高和MFR降低之间存在显著关系。经受试者工作特征曲线（Receiver Operating Characteristic Curve， ROC）分析，ApoB的预测值为0.87。结论：ApoB水平升高与CMD的严重程度相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Hypertension 医学-外周血管病

CiteScore

3.90

自引率

0.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical and Experimental Hypertension is a reputable journal that has converted to a full Open Access format starting from Volume 45 in 2023. While previous volumes are still accessible through a Pay to Read model, the journal now provides free and open access to its content. It serves as an international platform for the exchange of up-to-date scientific and clinical information concerning both human and animal hypertension. The journal publishes a wide range of articles, including full research papers, solicited and unsolicited reviews, and commentaries. Through these publications, the journal aims to enhance current understanding and support the timely detection, management, control, and prevention of hypertension-related conditions. One notable aspect of Clinical and Experimental Hypertension is its coverage of special issues that focus on the proceedings of symposia dedicated to hypertension research. This feature allows researchers and clinicians to delve deeper into the latest advancements in this field. The journal is abstracted and indexed in several renowned databases, including Pharmacoeconomics and Outcomes News (Online), Reactions Weekly (Online), CABI, EBSCOhost, Elsevier BV, International Atomic Energy Agency, and the National Library of Medicine, among others. These affiliations ensure that the journal's content receives broad visibility and facilitates its discoverability by professionals and researchers in related disciplines.